Home › Trials › NCT06894628
Clinical trial Recruiting at 1 site Observational Men only

Evaluating genomic testing and radiotherapy for prostate cancer recurrence

Official title: Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation

Run by Regina Elena Cancer Institute · NCT06894628 · Data updated 2026-11-12

This study is testing if a genomic test can help guide radiation treatment for men whose prostate cancer comes back after surgery.

Quick facts

Study typeObservational
SexMen only
Enrollment103 (estimated)
SponsorRegina Elena Cancer Institute
Academic / other
Locations1 site (Roma)
StatusRecruiting
StartedNovember 4, 2024
Main results expectedNovember 4, 2027
Study endsNovember 4, 2027
Registry record updatedMarch 25, 2025
Trial IDNCT06894628 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients who have had a radical prostatectomy and are experiencing biochemical recurrence.

Probably not a fit

Patients who do not meet the inclusion criteria for the esSBRT protocol or those with contraindications for salvage radiotherapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to validate the Decipher® genomic test in patients who experience biochemical recurrence after radical prostatectomy. Participants will receive salvage radiotherapy using extreme hypofractionation, delivering 5 Gy per fraction over five sessions. The study will also profile prostate cancer samples to identify specific molecular alterations related to risk stratification. By correlating genomic risk classes with disease progression, the study seeks to enhance predictive evaluations for treatment outcomes.

Why it matters

Potential benefit: If successful, this study could improve treatment personalization for patients with recurrent prostate cancer, potentially leading to better outcomes.

How similar studies have gone: Other studies have shown promise in using genomic classifiers for treatment stratification in prostate cancer, suggesting a potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* patients enrolled at IRE under the "esSBRT" protocol (meeting the criteria of the same);
* patients who express written informed consent personally or through their legal representative/witness/curator/guardian/support administrator (participation in the ancillary study and data processing)

Exclusion Criteria:

* all exclusion criteria adopted for the "esSBRT" study.

Where it's running

  • IRCSS Regina Elena
    Roma, Italy     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostatic Neoplasms 37Regina Elena Cancer Institute 29
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.